Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder
NCT03545191
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
930
Enrollment
INDUSTRY
Sponsor class
Conditions
Insomnia Disorder
Interventions
DRUG:
Daridorexant 25 mg
DRUG:
Daridorexant 50 mg
OTHER:
Placebo
Sponsor
Idorsia Pharmaceuticals Ltd.